The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1830-1840

  Morande, Pablo E ^a   Zanetti, Samanta R ^a   Borge, Mercedes ^a   Nannini, Paula ^a   Jancic, Carolina ^a   Bezares, Raimundo F ^c   Bitsmans, Alicia ^d   González, Miguel ^a   Rodríguez, Andrea L ^a   Galmarini, Carlos M ^e   Gamberale, Romina ^a,b   Giordano, Mirta ^a,b  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Hospital General De Agudos Teodoro Alvarez   (Argentina)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

^e Cell Biology Department   (Spain)

Author keywords

Aplidin; Chronic lymphocytic leukemia; Monocytes; Myeloid cells; Plitidepsin; Tumor microenvironment

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CASPASE 3; DEHYDRODIDEMNIN B; FLUDARABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE CLONE; MALE; MONOCYTE; NATURAL KILLER CELL; NURSE LIKE CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL DEATH; CELL SURVIVAL; CYCLOPHOSPHAMIDE; DEPSIPEPTIDES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MONOCYTES; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; VIDARABINE;

EID: 84867877192     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9740-3     Document Type: Article

References (36)

1. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, et al. (2008) Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 68:5216-5225
2. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477
3. Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J (2001) Marine organisms as a source of new anticancer agents. Lancet Oncol 2:221-225
4. Suarez Y, Gonzalez-Santiago L, Zarich N, Davalos A, Aranda JF, Alonso MA, Lasuncion MA, Rojas JM, Munoz A (2006) Plitidepsin cellular binding and rac1/jnk pathway activation depend on membrane cholesterol content. Mol Pharmacol 70:1654-1663
5. Munoz-Alonso MJ, Gonzalez-Santiago L, Martinez T, Losada A, Galmarini CM, Munoz A (2009) The mechanism of action of plitidepsin. In: Current opinion in investigational drugs. 10:536-542
6. Le Tourneau C, Faivre S, Ciruelos E, Dominguez MJ, Lopez-Martin JA, Izquierdo MA, Jimeno J, Raymond E (2010) Reports of clinical benefit of plitidepsin (aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma. Am J Clin Oncol 33:132-136
7. Eisen T, Thomas J, Miller WH, Jr., Gore M, Wolter P, Kavan P, Martin JA, Lardelli P (2009) Phase ii study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res 19:185-192. 33
8. Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, Garcia-Sanz R, Extremera S, Szyldergemajn S, Corrado C, et al. (2010) Phase ii clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res 16:3260-3269
9. Hallek M (2010) Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 23:85-96
10. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC (2010) The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116:3705-3714
11. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164-1174
12. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804-815
13. Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017-1029
14. Gamberale R, Geffner J, Arrosagaray G, Scolnik M, Salamone G, Trevani A, Vermeulen M, Giordano M (2001) Non-malignant leukocytes delay spontaneous b-cll cell apoptosis. Leukemia 15:1860-1867
15. Ghia P, Chiorazzi N, Stamatopoulos K (2008) Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 264:549-562
16. Riches JC, Ramsay AG, Gribben JG (2010) T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 20:431-438
17. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia b cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96:2655-2663
18. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ (2005) Nurselike cells express baff and april, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of sdf-1alpha. Blood 106:1012-1020
19. Eichhorst B, Hallek M, Dreyling M (2009) Chronic lymphocytic leukemia: Esmo minimum clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):102-104
20. Borge M, Nannini PR, Galletti JG, Morande PE, Avalos JS, Bezares RF, Giordano M, Gamberale R (2010) Cxcl12-induced chemotaxis is impaired in t cells from patients with zap-70-negative chronic lymphocytic leukemia. Haematologica 95:768-775
21. Fernandez Calotti P, Galmarini CM, Canones C, Gamberale R, Saenz D, Avalos JS, Chianelli M, Rosenstein R, Giordano M (2008) Modulation of the human equilibrative nucleoside transporter1 (hent1) activity by IL-4 and PMA in b cells from chronic lymphocytic leukemia. Biochem Pharmacol 75:857-865
22. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
23. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M (2011) IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 25:828-837
24. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP (1998) Annexin v-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9
25. Gajate C, An F, Mollinedo F (2003) Rapid and selective apoptosis in human leukemic cells induced by aplidine through a fas/cd95- and mitochondrial- mediated mechanism. Clin Cancer Res 9:1535-1545
26. Garcia-Fernandez LF, Losada A, Alcaide V, Alvarez AM, Cuadrado A, Gonzalez L, Nakayama K, Nakayama KI, Fernandez-Sousa JM, Munoz A, Sanchez-Puelles JM (2002) Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated jnk and p38 activation and protein kinase c delta. Oncogene 21:7533-7544
27. Taddei ML, Chiarugi P, Cuevas C, Ramponi G, Raugei G (2006) Oxidation and inactivation of low molecular weight protein tyrosine phosphatase by the anticancer drug aplidin. Int J Cancer 118:2082-2088
28. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, Martinez T, Fernandez-Sousa JM, Sanchez-Puelles JM, Munoz A (2003) Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, src, jnk, and p38 mapk. J Biol Chem 278:241-250
29. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A, de Braud F, Jimeno J, D'Incalci M (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65:2964-2971
30. D'Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9:2157-2163
31. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70:2235-2244
32. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174
33. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231-237
34. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499-4506
35. Baran CP, Zeigler MM, Tridandapani S, Marsh CB (2004) The role of ROS and RNS in regulating life and death of blood monocytes. Curr Pharm Des 10:855-866
36. Zurgil N, Solodeev I, Gilburd B, Shafran Y, Afrimzon E, Avtalion R, Shoenfeld Y, Deutsch M (2004) Monitoring the apoptotic process induced by oxidized low-density lipoprotein in Jurkat T-lymphoblast and U937 monocytic human cell lines. Cell Biochem Biophys 40:97-113